pharmaceuticals

Stifel initiated coverage on Inozyme Pharma Inc. (NASDAQ:INZY), saying, “This under-the-radar stock could be worth a look ahead of it.” The company’s lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine,...

Eyenovia Inc (NASDAQ:EYEN) shares are surging Monday in response to the company’s announcement of the launch of a new FDA-approved ophthalmic drug in collaboration with Formosa Pharmaceuticals. Key Developments: Eyenovia and Formosa Pharma have launched APP13007 (Clobetasol Propionate...

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares were trading lower Tuesday, closing down 14.61% at 38 cents. The stock is pulling back after gaining as much as 60% during Monday’s session after the company reported second-quarter financial results. The company early Tuesday also said...

On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound. Without giving any specific details, the pharmaceutical company did reveal it reached...

Eli Lilly and Company (NYSE:LLY) stock is trading lower on Friday. The company is anticipated to release earnings on Aug. 8 for the 2024 fiscal year second quarter. Also, Eli Lilly announced promising results from its SUMMIT phase 3 clinical trial earlier this week. The Details: Analyst estimates...

Moderna, Inc. (NASDAQ:MRNA) shares are getting hit because of a bad earnings report. The Street didn't like the numbers. The shares have broken a support level and may form a new downtrend. This is why Moderna is our Stock of the Day. If a stock is trending lower, there is more supply than demand....

Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9. Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with its clean...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is reportedly in active discussions to settle a lawsuit with the U.S. Department of Justice (DOJ). The lawsuit alleges Teva used charitable organizations to cover Medicare patients’ out-of-pocket costs, effectively paying kickbacks to boost sales...

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial...

Equillium Inc. (NASDAQ:EQ) announced Tuesday topline data from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with alopecia areata. Alopecia is an autoimmune disease that attacks the body’s hair follicles, causing patchy hair loss. The primary objectives of...

FibroGen Inc (NASDAQ:FGEN) shares are moving higher in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also announced a new clinical trial supply agreement with Regeneron. What Happened: After the market...

Pfizer Inc. (NYSE:PFE) has recently launched a multi-year cost reduction initiative aimed at saving approximately $1.5 billion by the end of 2027. This new program builds upon a $4 billion cost reduction plan announced last year. The move came as the pharmaceutical giant faces declining investor...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are rising in Thursday’s after-hours session following the company’s first-quarter financial results. Q1 Earnings: Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to...

Allarity Therapeutics Inc (NASDAQ:ALLR) shares are trading higher on a strong session volume of 67 million, as per the data from Benzinga Pro. The company announced the early discontinuation of its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer....

The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate the availability of more affordable alternatives to brand-name drugs, including blockbusters like Novo Nordisk A/S’s (NYSE:NVO) Ozempic...